Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

New sugar-test may reduce false-positive ovarian cancer screening tests

The world's most widespread test for ovarian cancer reports false-positives in 94 of 100 diagnosed cases. Now, chemists at the University of Copenhagen working with clinical researchers at University College London have developed a method able to halve the number of false-positives. When fully developed, the new test will spare a significant number of women from unnecessary worry and further testing. Furthermore, global health care providers stand to save substantial sums - just by including a test on a certain sugar molecule in tandem with the currently prevailing diagnostic test.

10 Mar 2014

BWH researchers explore newer approaches to treat Alzheimer's disease

A team of Alzheimer's disease (AD) researchers at Brigham and Women's Hospital (BWH) has been able to study the underlying causes of AD and develop assays to test newer approaches to treatment by using stem cells derived from related family members with a genetic predisposition to (AD).

7 Mar 2014

Ludwig, Agenus to advance three monoclonal antibody checkpoint modulators into preclinical development

Ludwig Cancer Research and Agenus Inc. today announced the selection of three monoclonal antibody checkpoint modulators (CPMs) that Agenus is advancing into preclinical development.

7 Mar 2014

Novel cancer immunotherapy approach may provide new weapon against most deadly tumors

A novel approach to cancer immunotherapy - strategies designed to induce the immune system to attack cancer cells - may provide a new and cost-effective weapon against some of the most deadly tumors, including ovarian cancer and mesothelioma.

6 Mar 2014

Scientists discover fundamental aggravating factor in autoimmune diseases

Scientists in Freiburg may have discovered a fundamental aggravating factor in autoimmune diseases. If B-lymphocytes lack the protein PTP1B, the cells will become hyperactive for stimulatory signals and can thus promote an autoimmune attack.

6 Mar 2014

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Agenus Inc., a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced its financial results and business highlights for the fourth quarter and year ended December 31, 2013.

5 Mar 2014

Researchers develop adjuvant which enhances effect of virus transduction

Lentiviruses, which belong to the family of retroviruses, are used as vectors to exchange genetic material in cells and can be used to replace a defective gene as defined by gene therapy.

5 Mar 2014

Eisai collaborates with Biogen Idec to develop and commercialize treatment options for AD

Eisai Co., Ltd. and Biogen Idec announced today that they have entered into a collaboration to develop and commercialize two of Eisai's clinical candidates for Alzheimer's disease (AD), E2609 and BAN2401.

5 Mar 2014

Researchers find antibody that may be used in future treatments for recurrent small-cell lung cancer

Researchers at Norris Cotton Cancer Center have found an antibody that may be used in future treatments for recurrent small-cell lung cancer, which currently has no effective therapy.

5 Mar 2014

Experimental drug nivolumab shrinks tumors in patients with advanced melanoma

An experimental drug aimed at restoring the immune system's ability to spot and attack cancer halted cancer progression or shrank tumors in patients with advanced melanoma, according to a multisite, early-phase clinical trial at Johns Hopkins Kimmel Cancer Center and 11 other institutions. All patients had experienced disease progression despite prior systemic therapies, and most had received two or more prior treatments.

4 Mar 2014

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

Omeros Corporation today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin‑associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.

4 Mar 2014

FDA clears First Response Gold Digital Pregnancy Test

Church & Dwight Co., Inc. announced today that the U.S. Food and Drug Administration has cleared the First Response Gold Digital Pregnancy Test to determine if a woman is pregnant up to six (6) days before her missed period and with over 99% accuracy from the day of her expected period – a significant step in pregnancy test innovation.

4 Mar 2014

AJT describes novel approach to long-term tolerance in organ transplantation

REGiMMUNE Corporation announced that the American Journal of Transplantation (AJT) has published its paper that describes a novel approach to long-term tolerance in organ transplantation with continuous administration of immune suppressants.

4 Mar 2014

New findings point the way toward potentially more effective HIV vaccine

In an advance for HIV vaccine research, a scientific team has discovered how the immune system makes a powerful antibody that blocks HIV infection of cells by targeting a site on the virus called V1V2.

4 Mar 2014

Food allergy increases among black children, say researchers

Children's food allergies are gradually increasing, but they may be as much as doubling among black children. According to a study published today in the March issue of Annals of Allergy, Asthma and Immunology, the scientific publication of the American College of Allergy, Asthma and Immunology (ACAAI), self-reported food allergy nearly doubled in black children over 23 years.

3 Mar 2014

Dyax reports total revenues of $16.9 million for fourth quarter 2013

Dyax Corp. today announced financial results for the fourth quarter and year ended December 31, 2013.

28 Feb 2014

Penn research team discovers new cost-effective way to fight rare blood disorder

A University of Pennsylvania research team has defined a possible new way to fight a disease that is currently treatable only with the most expensive drug available for sale in the United States.

28 Feb 2014

Penn researchers identify possible new way to fight rare blood disorder

A University of Pennsylvania research team has defined a possible new way to fight a disease that is currently treatable only with the most expensive drug available for sale in the United States. In a study published this month in Blood, the Penn team describes the strategy, based on the oldest part of the human immune system - called "complement" -- that could turn out to be less costly and more effective for the majority of patients with a rare blood disorder.

27 Feb 2014

Researchers discover new target for human antibodies that holds key to vaccine for dengue

Creating a vaccine that protects people from all four types of dengue virus has frustrated scientists for decades. But researchers at the University of North Carolina have discovered a new target for human antibodies that could hold the key to a vaccine for the world's most widespread mosquito-borne disease.

27 Feb 2014

Somali Americans develop twice antibody response to rubella from current vaccine

Somali Americans develop twice the antibody response to rubella from the current vaccine compared to Caucasians in a new Mayo Clinic study on individualized aspects of immune response.

27 Feb 2014

Antibody News and Research

Further Reading

New sugar-test may reduce false-positive ovarian cancer screening tests

BWH researchers explore newer approaches to treat Alzheimer's disease

Ludwig, Agenus to advance three monoclonal antibody checkpoint modulators into preclinical development

Novel cancer immunotherapy approach may provide new weapon against most deadly tumors

Scientists discover fundamental aggravating factor in autoimmune diseases

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Researchers develop adjuvant which enhances effect of virus transduction

Eisai collaborates with Biogen Idec to develop and commercialize treatment options for AD

Researchers find antibody that may be used in future treatments for recurrent small-cell lung cancer

Experimental drug nivolumab shrinks tumors in patients with advanced melanoma

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

FDA clears First Response Gold Digital Pregnancy Test

AJT describes novel approach to long-term tolerance in organ transplantation

New findings point the way toward potentially more effective HIV vaccine

Food allergy increases among black children, say researchers

Dyax reports total revenues of $16.9 million for fourth quarter 2013

Penn research team discovers new cost-effective way to fight rare blood disorder

Penn researchers identify possible new way to fight rare blood disorder

Researchers discover new target for human antibodies that holds key to vaccine for dengue

Somali Americans develop twice antibody response to rubella from current vaccine

Immunology eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News